Acurion
AI analysis of routine pathology images to identify cancer biomarkers for precision oncology.
$4.3MSeed
Role not disclosedMV
Mesa Verde Venture Partners
Activity from announced rounds
Activity in this selectionAI
Mesa Verde Venture Partners is the venture organization identified in Acurion and Tempo financing coverage.
Recorded funding activity
Acurion analyzes pathology images for cancer biomarkers. Tempo develops injectable scaffolds intended to support tissue regeneration. The company records distinguish diagnostic software from regenerative-medicine development.
- Rounds participated in
- 1
- Confirmed lead rounds
- — 1 roles undisclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $4.3M 1 disclosed · full round size, not this investor’s share